AstraZeneca PLC (LON:AZN) Stock Has Consensus Price Target of £150 According to Analysts

Shares of AstraZeneca PLC (LON:AZN) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is £153.57.

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price target on shares of AstraZeneca in a research report on Tuesday, September 29th. Jefferies Financial Group restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a report on Wednesday. Citigroup lifted their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Berenberg Bank reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Wednesday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a £145 target price on shares of AstraZeneca in a report on Tuesday, September 8th.

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Michel Demare purchased 2,500 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average cost of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Price Performance

LON:AZN opened at £119.98 on Friday. The stock has a 50 day moving average of £120.45 and a two-hundred day moving average of £131.98. AstraZeneca has a 12 month low of £114.04 and a 12 month high of £157.32. The firm has a market cap of £186.08 billion, a P/E ratio of 17.96, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.